Editors: Atta-ur-Rahman, Mohammad Iqbal Choudhary

Drug Design and Discovery in Alzheimer’s Disease

Republished Version of Frontiers in Drug Design and Discovery Volume 6

eBook: US $165 Special Offer (PDF + Printed Copy): US $317
Printed Copy: US $235
Library License: US $660
ISSN: 1574-0889 (Print)
ISSN: 2212-1064 (Online)
ISBN: 978-0-12-803959-5 (Print)
ISBN: 978-012-803960-1 (Online)
Year of Publication: 2014
DOI: 10.1016/c2014-0-04317-1

Introduction

“Frontiers in Drug Design and Discovery” is an Ebook series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The Ebook series should prove to be of interest to all the pharmaceutical scientists involved in research in drug design and discovery. Each volume is devoted to the major advances in drug design and discovery. The Ebook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

The sixth volume of this Ebook series focuses on drug discovery and design strategies for the treatment of Aheimer’s Diseases and related neurodegenerative disorders.

Indexed in: Book Citation Index, Science Edition, BIOSIS Previews, Scopus, EMBASE, Scilit, EBSCO, Ulrich's Periodicals Directory.

Preface

- Pp. i-iii (3)
Atta-ur-Rahman, M. Iqbal Choudhary
Download Free

List of Contributors

- Pp. iv-xi (8)
Atta-ur-Rahman, M. Iqbal Choudhary
Download Free

Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives

- Pp. 3-39 (37)
Jan Korabecny, Filip Zemek, Ondrej Soukup, Katarina Spilovska, Kamil Musilek, Daniel Jun, Eugenie Nepovimova, Kamil Kuca
View Abstract

Challenges in Designing Therapeutic Agents for Treating Alzheimer’s Disease-from Serendipity to Rationality

- Pp. 40-141 (102)
Umer Rashid, Farzana L. Ansari
View Abstract

Enzyme Inhibitors Involved in the Treatment of Alzheimer’s Disease

- Pp. 142-198 (57)
Vageesh Revadigar, Raza Murad Ghalib, Vikneswaran Murugaiyah, Mohamed A. Embaby, Ali Jawad, Sayed Hasan Mehdi, Rokiah Hashim, Othman Sulaiman
View Abstract

Towards Small Molecules as Therapies for Alzheimer’s Disease and Other Neurodegenerative Disorders

- Pp. 199-290 (92)
Omar Aziz, Roland W. Bürli, David F. Fischer, Julie Frearson, Michael D. Wall
View Abstract

Multifunctional Enzyme Inhibition for Neuroprotection - A Focus on MAO, NOS, and AChE Inhibitors

- Pp. 291-365 (75)
Jacques Joubert, Jacobus P. Petzer, Louis H.A. Prins, Benjamin P. Repsold, Sarel F. Malan
View Abstract

Specific Cholinesterase Inhibitors: A Potential Tool to Assist in Management of Alzheimer Disease

- Pp. 366-386 (21)
Nigel H. Grieg, Mohammad A. Kamal, Nasimudeen R. Jabir, Shams Tabrez, Faizul H. Nasim, Adel M. Abuzenadah, Gjumrakch Aliev
View Abstract

Role of Acetylcholinesterase Inhibitors and Alzheimer Disease

- Pp. 387-425 (39)
Zafar Saied Saify, Nighat Sultana
View Abstract

Research Strategies Developed for the Treatment of Alzheimer’s Disease. Reversible and Pseudo-Irreversible Inhibitors of Acetylcholinesterase: Structure-Activity Relationships and Drug Design

- Pp. 426-477 (52)
Mauricio Alcolea-Palafox, Paloma Posada-Moreno, Ismael Ortuño- Soriano, José L. Pacheco-del-Cerro, Carmen Martínez-Rincón, Dolores Rodríguez-Martínez, Lara Pacheco-Cuevas
View Abstract

Modulation of BACE1 Activity as a Potential Therapeutic Strategy for Treating Alzheimer’s Disease

- Pp. 478-517 (40)

View Abstract

BACE1 Inhibitors: Attractive Therapeutics for Alzheimer’s Disease

- Pp. 518-546 (29)
Boris Decourt, MiMi Macias, Marwan Sabbagh, Abdu Adem
View Abstract

Combining BACE1 Inhibition with Metal Chelation as Possible Therapy for Alzheimer’s Disease

- Pp. 547-565 (19)
Maged M. Henary, Tyler L. Dost, Eric A. Owens, Surendra Reddy Punganuru
View Abstract

Somatostatin Receptor-4 Agonists as Candidates for Treatment of Alzheimer’s Disease

- Pp. 566-597 (32)
Karin E. Sandoval, Kenneth A. Witt, A. Michael Crider, Maria Kontoyianni
View Abstract

Neprilysin Inhibitors Provide Insight into its Specificity and Therapeutic Potential

- Pp. 598-622 (25)
Darrick Pope, Michael Cascio
View Abstract

Targeting the GSK3β/β-catenin Signaling to Treat Alzheimer´s Disease: Plausible or Utopic?

- Pp. 623-642 (20)
Fares Zeidán-Chuliá, José Cláudio Fonseca Moreira
View Abstract

Targets and Small Molecules Against Tauopathies. Part 1: From Genes to Soluble, Aggregation-Prone Tau Proteins

- Pp. 643-715 (73)
Pierfausto Seneci
View Abstract

Nanomedicine Based Drug Targeting in Alzheimer’s Disease: High Impact of Small Carter

- Pp. 716-739 (24)
Mohammad Zaki Ahmad, Sohail Akhter, Ziyaur Rahman, Javed Ahmad, Iqbal Ahmad, Farhan Jalees Ahmad
View Abstract

Index

- Pp. 740-766 (27)
Atta-ur-Rahman, M. Iqbal Choudhary
Download Free

RELATED BOOKS

.Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II.
.Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I.
.Frontiers in Cardiovascular Drug Discovery.
.Frontiers in Drug Design and Discovery.